News and trends on diagnostics testing, insurance coverage, and reimbursement.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The long-term pricing contract covers hereditary cancer testing, GeneSight, and a number of other diagnostics, but doesn't extend to coverage.
The company has secured coverage for its pigmented lesion assay from CareFirst Blue Cross/Blue Shield and affiliate CareFirst BlueChoice.
The company said the number of lives now covered for EndoPredict has gone up to 109 million.
